ArticleCureus2026
Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy: A Marker of Disease Severity but Not an Independent Predictor of Mortality.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atrial fibrillation in transthyretin amyloid cardiomyopathy: marker of disease severity and implications for multidomain reassessment.Heart failure reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Atrial fibrillation (AF) is the most common arrhythmia in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), although its prognostic role remains uncertain. There is substantial evidence regarding mortality when AF coexists with heart failure (HF). However, this association is not well established in patients with ATTR-CM. This study aimed to assess whether AF was an independent predictor of all-cause mortality in ATTR-CM. Methods A total of 22 patients with confirmed ATTR-CM were followed (mean follow-up: 18.2 ± 6.8 months). The association between AF and all-cause mortality was evaluated using Cox proportional hazards modeling. Results The cohort had a mean age of 72 years (AF: 75.0 ± 5.5 years vs. no AF: 69.0 ± 8.7 years), and 81.8% of patients were men. Nine (41%) patients died during follow-up; among these, six (67%) had AF. AF was present in 11 (50%) of patients. AF was associated with more advanced disease, including a higher proportion of ATTR stage III (45.5% vs. 18.2%; p = 0.14) and New York Heart Association (NYHA) class III-IV symptoms (81.8% vs. 54.5%; p = 0.13). AF was not associated with all-cause mortality in the unadjusted analysis (hazard ratio (HR) 2.12; 95% confidence interval (CI): 0.53-8.52) or after adjustment for age, ATTR stage III vs. I-II, and left ventricular global longitudinal strain (LVGLS) > -15% (HR: 0.90; 95% CI: 0.12-6.98). In contrast, ATTR stage III vs. I-II remained an independent predictor of mortality (HR: 7.05; 95% CI: 1.55-31.98). Conclusions Patients with ATTR-CM carry a high mortality burden. AF is a common rhythm disorder in this population and appears to represent a more advanced disease phenotype rather than an independent predictor of all-cause mortality. These findings suggest that AF may function as a marker of disease progression and a valuable element for clinical stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.